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AbstrACt
background A minority of patients with advanced non- 
small- cell lung cancer (NSCLC) benefit from treatment with 
immune checkpoint inhibitors (ICIs). Ineffective effector 
function of activated T and NK cells may lead to reduced 
tumor cell death, even when these activated effector 
cells are released from their immune checkpoint brake. 
Hence, in this study we aimed to assess the association of 
baseline serum granzyme B, as well as germline variation 
of the GZMB gene, with clinical outcome to programmed 
cell death protein 1 (PD-1) blockade.
Methods A total of 347 patients with stage IV NSCLC 
who started nivolumab treatment between June 2013 
and June 2017 were prospectively included. Baseline 
serum and whole blood was available, allowing for protein 
quantification and targeted DNA sequencing. Clinical 
outcome was based on best overall response (BOR) 
according to Response Evaluation Criteria in Solid Tumors, 
V.1.1, progression- free survival (PFS), and overall survival 
(OS).
results Patients with low serum levels of granzyme B 
had worse PFS (HR: 1.96; 95% CI: 1.12 to 3.43; p=0.018) 
and worse OS (HR: 2.08; 95% CI: 1.12 to 3.87; p=0.021) 
than patients with high baseline serum levels. To validate 
the findings, germline variation of GZMB rs8192917 was 
assessed. Patients with homozygous and heterozygous 
variants of GZMB rs8192917 had worse BOR (OR: 1.60; 
95% CI: 1.01 to 2.52; p=0.044) and worse PFS (HR: 1.38; 
95% CI:1.02 to 1.87; p=0.036) than wild types.
Conclusions A low baseline serum level of granzyme 
B and germline variation of GZMB was associated with 
worse clinical outcome in NSCLC, emphasizing the 
relevance and additional value of monitoring germline 
genetic variations which mirror cytotoxic functions of T 
cells in ICI therapy.
trail registration number Dutch Trial Registry (NL6828).
bACkground
Immune checkpoint inhibitors (ICIs) target 
immune effector cells, predominantly T 
cells, which may lead to an effective immune 
response toward tumor cells.1 2 Although ICIs 
have shown to significantly improve overall 
survival (OS) in advanced non- small- cell lung 
cancer (NSCLC), only a minority of patients 
benefit from treatment, with an objective 
response in about one out of five patients.3 4
The molecular mechanisms underlying 
resistance to ICI therapy are only partly 
explained. It is postulated that a combination 
of factors contribute to response, involving 
tumor biology, tumor microenvironment, 
the peripheral immune system, as well as 
germline genetics.5 6 programmed cell death 
protein 1 (PD-1)- mediated inhibition targets 
signaling downstream of the T cell receptor 
via its downstream phosphatase SHP-2, as 
well as costimulatory molecules.7 8 Impor-
tantly, distorted effector function of activated 
T and NK cells may lead to reduced tumor 
cell death, even when these activated effector 
cells are released from their PD-1 brake.
Previously, it has been demonstrated that 
immunohistochemical staining and in vivo 
imaging, using positron emission tomog-
raphy, of intratumoral granzyme B may serve 
as a predictive biomarker for PD-1 blockade 
in melanoma.9 Granzyme B is a key serine 
protease that is secreted to induce apoptosis, 
primarily by activated T cells and NK cells.10 
Distortion of granzyme B activity could be 
linked to reduced entry, trafficking, and accu-
mulation within the cytoplasm of target cells 
(eg, tumor cells), and/or linked to reduced 
enzymatic activity, and hence decreased 
cleavage of intracellular substrates, such as 
caspase-3.11–13
Taken together, we hypothesize that low 
baseline serum levels of granzyme B, and 
consequently alterations of the GZMB locus, 
may contribute to resistance mechanisms of 
PD-1 blockade. The primary objectives of the 
current analysis were to assess the association 
of baseline serum granzyme B levels with 
progression- free survival (PFS) and OS after 
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PD-1 blockade in patients with NSCLC. As a validation, 
genetic variants of the GZMB gene were related with PFS, 
OS and best overall response (BOR). Secondary objec-
tives were to assess the relationship between serum gran-
zyme B as well as genetic variations of GZMB and cytotoxic 
immune cell populations in blood.
Methods
study design and data collection
Patients with advanced NSCLC who were treated with 
PD-1 ICIs between June 2013 and June 2017 at the 
Erasmus University MC (Rotterdam, The Netherlands) 
and the Amphia Hospital (Breda, The Netherlands) were 
prospectively included. Patients with NSCLC stage IV who 
had been treated with nivolumab monotherapy (3 mg/
kg intravenous, once every 2 weeks) were included, and 
patients who were treated with a prior line of immuno-
therapy were excluded from the study. The study was 
approved by the independent ethics committee board 
(MEC 02-1002 and MEC 16-011) and all patients provided 
written informed consent. Whole blood and baseline 
serum were available for DNA analysis and protein 
quantification, respectively. All assays were performed 
blinded to study endpoints; patients were assigned to a 
subject number. Patient characteristics included demo-
graphic and clinical data. BOR was assessed according 
to the Response Evaluation Criteria in Solid Tumors 
V.1.1 (RECIST V.1.1).14 A minimum duration of 90 days 
for stable disease (SD) was required. Confirmation of 
partial response (PR) or complete response (CR) was 
not required. After treatment initiation, radiological eval-
uation by CT was usually performed every 6 weeks. PFS 
was defined as the time from the first administration of 
nivolumab until progressive disease (PD), or death due 
to any cause, whichever occurred first. OS was defined as 
the time from the first administration of nivolumab until 
death due to any cause.
Quantitative protein measurement and dnA analysis
Quantitative analysis of granzyme B in serum was 
performed by a magnetic bead- based assay, using a 1×96- 
well microplate and magnetic antigranzyme- B- coated 
beads (Human Magnetic Luminex Assay, R&D Systems 
Inc, Minneapolis, Minnesota, USA). GZMB c.128T>C 
(rs8192917) was selected primarily based on its presumed 
contribution to resistance mechanisms of ICIs.9 A total of 
12 single- nucleotide polymorphisms (SNPs) were selected 
in eight genes based on their contribution to T cell immu-
nity and their correlation with overt T cell responses, such 
as the autoimmune diseases systemic lupus erythema-
tosus and rheumatoid arthritis.15 16–25 A summary of the 
correlation of selected SNPs with overt T cell responses 
is displayed in online supplementary table 1. SNPs with 
a minor allele frequency (MAF) of <5% were excluded 
from the analysis. Linkage disequilibrium was tested 
using the application LDmatrix of LDlink V.5 (https:// 
ldlink. nci. nih. gov/). Distribution of genotypes was tested 
for Hardy- Weinberg equilibrium (HWE) using the χ2 
test. Deviations from HWE may reflect genotyping errors, 
though, may also be a signal of disease association,26 for 
example, mutation of tumor suppressor genes. DNA 
isolation and genotyping for GZMB rs8192917, HLA- A 
rs60131261, IL10 rs3024493, IL2RA rs3024493, IFNG 
rs2430561/rs2069705/rs2069718, PDCD1 rs2227981/
rs10204525/rs2227982, PTPN11 rs2301756 and ZAP70 
rs13420683 has been performed using TaqMan analysis 
as previously described.27 Whole- blood specimens were 
used for extraction of DNA. Genotyping was performed 
using predesigned TaqMan allelic discrimination assays, 
consisting of two allele- specific minor groove- binding 
probes. PCRs were performed in a reaction volume 
containing DNA, primers, and the specific probes were 
labeled with fluorescent dye.
Flow cytometry
Peripheral blood samples were analyzed using multiplex 
flow cytometry as previously described by Kunert et al.6 
In short, absolute cell counts of immune cell populations 
were determined on whole blood after lysis of red blood 
cells, and frequencies of particular subsets were deter-
mined in more detail on cryopreserved peripheral blood 
mononuclear cell samples that were stained with a mix of 
antibodies.
Mutational burden and expression of Pd-L1 in tumor tissue
Expression of programmed death- ligand 1 (PD- L1) and 
tumor mutational burden (TMB) have previously been 
determined in a subset of patients of cohort 1 (n=26; 
patients with stage IV NSCLC) using archival formalin- 
fixed, paraffin- embedded tissue samples.28 Baseline 
expression of PD- L1 has been determined using antibody 
clone SP263 (Roche Diagnostics, Tucson, Arizona, USA), 
whereas TMB has been measured using the Oncomine 
TML assay (Thermofisher Scientific, Waltham, Massachu-
setts, USA).
statistical analysis
To study the relationship between baseline protein levels 
or SNPs and survival (PFS and OS), Cox regression anal-
ysis was used. Patient survival was visualized by the Kaplan- 
Meier approach. Patients were dichotomized for low or 
high granzyme B serum levels based on the median value 
of all patients. Dominant, recessive, and additive models29 
were used to test associations between SNPs and clinical 
outcomes including BOR, PFS, and OS. HRs and 95% CIs 
were calculated. For the association of SNPs with radio-
logical response, BOR was used as an ordered categorical 
variable with three levels, namely CR/PR (pooled), SD, 
and PD, by means of ordinal logistic regression analysis. 
This method assumes that the relationship between each 
pair of outcome groups is the same. The proportional 
odds assumption was checked for all analyses. Univariate 
ordinal logistic regression was applied for both SNPs and 
patient factors, and OR and 95% CIs were calculated. 
Multivariable ordinal logistic analysis was performed 
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Table 1 Patient characteristics
Cohort 1 (n=78) Cohort 2 (n=322)
Age at start
Mean (range in years) 63.6 (35–78) 64.7 (29–85)
n % n %
Sex
  Male 48 61.5 202 62.7
  Female 30 38.5 120 37.3
Primary tumor
  Adenocarcinoma 52 66.7 200 62.1
  Squamous cell 
carcinoma
17 21.8 96 29.8
  Large cell carcinoma – – 22 6.8
  Lung cancer with 
unknown pathology
9 11.5 4 1.2
WHO PS
  0 18 23.1 54 16.8
  1 39 50.0 188 58.4
  2 1 1.3 7 2.2
  3 – – 1 0.3
  Unknown 20 25.6 72 22.4
Prior lines
  0 2 2.6 1 0.3
  1 60 76.9 217 67.4
  2 13 16.7 82 25.5
  3 2 2.6 15 4.7
  4 1 1.3 6 1.9
  5 – – 1 0.3
Smoking status
  History or current 
smoker
56 71.8 238 73.9
  Never smoker 8 10.3 20 6.2
  Unknown 14 17.9 64 19.9
Ethnicity
  Caucasian 74 94.9 308 95
  Other 4 5.1 5 2
  Unknown 0 – 9 3
Baseline characteristics of NSCLC cohort 1 and cohort 2. 16.5% 
of the patients (n=53) from cohort 1 were overlapping with 
cohort 2.
NSCLC, non- small- cell lung cancer; WHO PS, WHO 
performance status.
including both single SNPs and patient factors, with 
p<0.1 according to the univariate analyses. All analyses, 
with a significant relation (p<0.05) between SNP and 
clinical outcome, were internally validated by bootstrap-
ping,30 where 1000 bootstrap samples were generated 
(with replacement) and 95% CIs were calculated for 
either ORs or HRs. Furthermore, bias and bias- corrected 
95% CIs were calculated. In general, a p value <0.05 was 
considered to be statistically significant. Analyses were 
performed using IBM SPSS Statistics V.24.0.0.1 (Chicago, 
Illinois, USA) and STATA V.15.1 (StataCorp LP, College 
Station, Texas, USA).
resuLts
Patient characteristics
Baseline serum from a total of 78 (cohort 1) and DNA 
from a total of 322 patients with stage IV NSCLC (cohort 
2) was available for analysis (table 1). There was a 16.5% 
subject overlap between the patient cohorts. All patients 
were treated with at least one dose of nivolumab at 3 mg/
kg once every 2 weeks. Overall, median absolute starting 
dose was 222 mg (IQR 192–263 mg). The objective 
response rate was similar in cohort 1 and cohort 2, respec-
tively 19.2% and 16.6%. A minority (7%) of all patients 
could not be evaluated for response by RECIST V.1.1 due 
to early death, loss to follow- up or incomplete or absent 
follow- up tumor assessments. In the univariate analysis 
of cohort 2, WHO performance status (0 vs ≥1) and sex 
(male vs female) were significantly associated with PFS 
(HR: 0.66; 95% CI: 0.46 to 0.95; p=0.027 and HR: 1.38; 
95% CI: 1.06 to 1.80; p=0.18, respectively) and OS (HR: 
0.52; 95% CI: 0.34 to 0.77; p=0.001 and HR: 1.40; 95% CI: 
1.05 to 1.86; p=0.023, respectively). In the multivariable 
analysis, only WHO performance status and primary 
tumor type remained significant for their association 
with, respectively PFS or OS and BOR.
serum levels of granzyme b are associated with clinical 
outcome
Serum levels of granzyme B were determined in cohort 
1 (online supplementary figure 1), having a median 
concentration of 1.27 pg/mL, which was used as the cut- 
off to dichotomize patients with low and high levels of 
serum granzyme B (as described in the Method section). 
Patients with low baseline serum levels of granzyme B had 
a significant worse PFS (HR: 1.96; 95% CI: 1.12 to 3.43; 
p=0.018, figure 1A) than patients with high levels of base-
line serum granzyme B. Likewise, low levels of granzyme 
B were significantly associated with worse OS (HR: 2.08; 
95% CI: 1.12 to 3.87; p=0.021, figure 1B) compared with 
high levels of granzyme B.
germline variation of GZMB is associated with clinical 
outcome
To validate the findings in a second cohort by a different 
approach,31 genetic alterations of GZMB c.128T>C 
(rs8192917), together with a mechanism- of- action- based 
panel of other SNPs, were related to PFS, OS and BOR 
in cohort 2. Investigated SNPs with the corresponding 
haplotype frequencies, MAF and HWE statistics are 
shown in online supplementary table 2. After correction 
for WHO performance status and sex in multivariable 
analysis, patients with homozygous and heterozygous 
variants of GZMB rs8192917 had worse PFS (HR: 1.38; 
95% CI: 1.02 to 1.87; p=0.036; table 2, figure 1C). This 
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Figure 1 Association of serum granzyme B and GZMB genotype with survival (A) Kaplan- Meier plots showing the (A) PFS (in 
days) and (B) OS (in days) of patients in cohort 2 (n=78) with low (in blue) versus high (in red) baseline serum levels of granzyme 
B. The (C) PFS and (D) OS of patients in cohort 2 (n=322) with wild type (in red) versus variant germline GZMB (in blue). 
Numbers at risk are shown below the graph. OS, overall survival; PFS, progression- free survival.
finding could be internally validated (HR 95% CI: 1.02 
to 1.87; bias: 0.003; bias- corrected 95% CI: 1.03 to 1.88; 
p=0.036; online supplementary table 3). Remaining SNPs 
were not associated with PFS after correction for patient 
factors (table 3). No significant association of SNPs 
with OS was observed after correction of patient factors 
(table 3). Of note, homozygous and heterozygous vari-
ants of GZMB rs8192917 were not significantly associated 
with OS (HR: 1.19; 95% CI: 0.91 to 1.57; p=0.212; table 2, 
figure 1D). Homozygous and heterozygous variants of 
GZMB rs8192917 were significantly associated with worse 
BOR (OR: 1.60; 95% CI: 1.01 to 2.52; p=0.044; table 2) 
and could be internally validated for the association with 
BOR (OR 95% CI: 1.05 to 2.55, bias: 0.007; bias- corrected 
95% CI: 1.09 to 2.57; p=0.030, online supplementary 
table 3). All the results from both univariate (p<0.1) and 
multivariate analyses of the association with PFS, OS or 
BOR are shown in table 3. Results from the internal vali-
dation of factors that were significantly associated after 
correction for patient factors (p value <0.05) are shown 
in online supplementary table 3. For a subset of patients, 
both serum levels of granzyme B and germline variation 
of GZMB c.128T>C (rs8192917) were available for anal-
ysis. Patients with homozygous and heterozygous variants 
of GZMB rs8192917 (n=19) had significant lower serum 
levels of granzyme B compared with patients with wild- 
type GZMB (n=34; mean difference 8.6 pg/mL, 95% CI 
1.77 to 15.38, p=0.015).
serum levels of granzyme b are accompanied by presence of 
t cells with terminal differentiation and exhausted phenotype
Next, we assessed the relationship between serum gran-
zyme B as well as genetic variations of GZMB and cyto-
toxic immune cell populations in blood. Overall, there 
was a tendency that patients with lower serum granzyme 
B levels had lower absolute numbers of peripheral CD56+ 
NK cells (mean 141 vs 205 cells/µL, p=0.16; online supple-
mentary figure 2) and CD8+ T cells (346 vs 463 cells/µL, 
p=0.41; figure 2A) when compared with patients with 
higher serum granzyme B levels. In fact, patients with 
homozygous or heterozygous variants of GZMB rs8192917 
had a higher number of CD8+ T cells but not CD56+ NK 
cells than patients with wild- type GZMB (figure 2B and 
online supplementary figure 2B). Further, we studied 
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Table 2 Association between GZMB genotype and clinical outcome
Parameter Test variables
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
PFS
  GZMB c.128T>C CC+CT vs TT 1.39 (1.07 to 1.80) 0.013* 1.38 (1.02 to 1.87) 0.036*
  WHO 0 vs ≥1 0.66 (0.46 to 0.95) 0.027* 0.61 (0.42 to 0.89) 0.01*
  Sex Male vs female 1.38 (1.06 to 1.80) 0.018* 1.29 (0.95 to 1.76) 0.103
OS           
  GZMB c.128T>C CC+CT vs TT 1.19 (0.91 to 1.57) 0.212     
  WHO 0 vs ≥1 0.52 (0.35 to 0.77) 0.001*     
  Sex Male vs female 1.40 (1.05 to 1.86) 0.023*     
Parameter  Test variables
Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
BOR
  GZMB c.128T>C CC +CT vs TT 1.63 (1.04 to 2.57) 0.033* 1.60 (1.01 to 2.52) 0.044*
  Primary tumor Other vs adeno 0.63 (0.40 to 0.98) 0.041* 0.63 (0.41 to 0.99) 0.045*
Univariate and multivariate analysis of the association of germline variation of GZMB and PFS, OS, or BOR. Patient factors associated with 
OS/PFS (p value<0.1) were included in the multivariate analysis. Significance is marked by *.
BOR, best overall response; OS, overall survival; PFS, progression- free survival; WHO, WHO performance status.
whether granzyme B levels or GZMB genotypes correlate 
with frequencies of those immune cell phenotypes that 
correspond to either terminal differentiation (CCR7-
CD45RA+) or exhaustion (PD1+ and TIM3+) of CD8+ T 
cells, as signs of T cell cytotoxicity. Interestingly, patients 
with lower serum granzyme B levels had a lower propor-
tion of CCR7−CD45RA+CD8+ T cells (mean 44 vs 54 %, 
p=0.040) as well as PD1+TIM3+CD8+ T cells (mean 4.5 vs 
7.8 %, p=0.001; figure 2A). No significant association nor 
trend could be observed between GZMB genotype and 
frequencies of T cells with these phenotypes (figure 2B).
relationship between serum granzyme b, expression of Pd-L1 
and tMb
Interaction analysis for PFS and OS was performed 
between serum granzyme B, and PD- L1 and TMB in a 
subset of evaluable patients. In the univariate analysis, 
TMB (HR: 7.31; 95% CI: 1.5 to 34.7; p=0.01) was signifi-
cantly correlated with PFS, while expression of PD- L1 
(HR: 4.30; 95% CI: 0.9 to 19.8; p=0.06) or serum gran-
zyme B (HR: 2.34; 95% CI: 0.9 to 5.9; p=0.07) did not 
meet the threshold for significance (online supplemen-
tary table 4). Moreover, only serum granzyme B was 
significantly correlated with OS (HR: 2.95; 95% CI: 1.09 
to 7.93; p=0.03; online supplementary table 5). Multivar-
iate analysis of these biomarkers (namely, serum gran-
zyme B, PD- L1 and TMB) for PFS and OS did not meet 
significance. Of note, the HRs were in favor of higher 
levels of PD- L1 (≥50%), TMB (≥10 mut/Mb) and serum 
granzyme B (≥1.27 pg/mL), yet expression of PD- L1 (%), 
TMB (mut/Mb) and serum granzyme B levels (pg/mL) 
were not significantly correlated with each other (online 
supplementary table 6).
disCussion
The present study demonstrates that serum levels of gran-
zyme B and alterations of the GZMB locus may contribute 
to resistance mechanisms of PD-1 blockade. This concept 
(figure 3) is based on our findings that (1) low serum 
levels of granzyme B and (2) a common germline poly-
morphism of the GZMB gene were associated with worse 
clinical outcome after PD-1 blockade in patients with 
metastatic NSCLC. Moreover, serum levels of granzyme B 
were positively correlated with peripheral abundance of 
T cell populations that were highly differentiated or were 
expressing the immune checkpoints PD-1 and TIM3. 
The results are inline with our hypothesis that cytotoxic 
effector functions of lymphocytes (ie, through gran-
zymes) are critical for the anti- PD-1 antibody- mediated 
immune effects.
Granzyme B levels were determined at baseline in 
patients with stage IV NSCLC prior to start with PD-1 
ICIs. The median granzyme B level in this cohort was 
1.27 pg/mL (range 0–88 pg/mL), which was lower than 
reported levels in healthy controls, for example, a median 
plasma granzyme B of 5.7 pg/mL (IQR 3.7–7.1 pg/mL; 
n=38)32 or 11.5 pg/mL (range 1–130 pg/mL; n=54).33 
Measurements of granzyme B in serum were consistent 
with measurements in plasma.33 Our findings confirm the 
hypothesis that lower granzyme B levels in patients with 
metastatic cancer mirror the immune microenvironment 
of tumors favoring tumor growth by halting the anti-
tumor response of cytotoxic immune cells. This may be a 
result of those germline variations that impact cytotoxic 
functions of lymphocytes.
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Table 3 Association between investigated SNPs and clinical outcome
Parameter Test variables HR (95% CI) P value
Univariate analysis (PFS)
  IFNG c.874T>A AA+AT vs TT 0.76 (0.58 to 0.99) 0.045
  IL2RA c.64+5006T>C CC+CT vs TT 0.80 (0.62 to 1.04) 0.098
  WHO performance status 0 vs ≥1 0.66 (0.46 to 0.95) 0.027
  Sex Male vs female 1.38 (1.06 to 1.80) 0.018
Multivariate analysis (PFS)
  IFNG c.874T>A AA+AT vs TT 0.79 (0.58 to 1.07) 0.131
  WHO performance status 0 vs ≥1 0.66 (0.45 to 0.95) 0.024
  Sex Male vs female 1.26 (0.92 to 1.71) 0.148
    
  IL2RA c.64+5006T>C CC+CT vs TT 0.81 (0.60 to 1.10) 0.177
  WHO performance status 0 vs ≥1 0.65 (0.45 to 0.93) 0.019
    
  Sex Male vs female 1.29 (0.95 to 1.76) 0.101
  IFNG c.874T>A AA+AT vs TT 0.76 (0.55 to 1.05) 0.093
  WHO performance status 0 vs ≥1 0.52 (0.34 to 0.77) 0.001
  Sex Male vs female 1.45 (1.03 to 2.02) 0.32
Univariate analysis (OS)
  IFNG c.874T>A AA+AT vs TT 0.72 (0.55 to 0.95) 0.021
  WHO PS 0 vs ≥1 0.52 (0.35 to 0.77) 0.001
  Sex Male vs female 1.40 (1.05 to 1.86) 0.023
Multivariate analysis (OS)
  IFNG c.874T>A AA+AT vs TT 0.76 (0.55 to 1.05) 0.093
  WHO performance status 0 vs ≥1 0.52 (0.34 to 0.77) 0.001
  Sex Male vs female 1.45 (1.03 to 2.02) 0.32
Parameter Test variables OR (95% CI) P value
Univariate analysis (BOR)
  IL10 c.387+284C>A AA vs AA +AC 0.25 (0.07 to 0.89) 0.033
  ZAP70 −21–4127C>A AA vs CC+AC 0.50 (0.25 to 0.98) 0.045
  Primary tumor Other vs adeno 0.63 (0.40 to 0.98) 0.041
  Multivariate analysis (BOR)     
  IL10 c.387+284C>A AA vs AA +AC 0.24 (0.07 to 0.84) 0.026
  Primary tumor Other vs adeno 0.61 (0.39 to 0.96) 0.031
    
  ZAP70 −21–4127C>A AA vs CC+AC 0.49 (0.24 to 0.97) 0.042
  Primary tumor Other vs adeno 0.61 (0.39 to 0.96) 0.033
Univariate and multivariate analysis of the association between germline SNPs (except those related to GZMB variation; those are shown in 
table 2) and PFS, OS, or BOR. Only SNPs that were associated with OS/PFS/BOR (p value <0.1) are shown and included in the multivariate 
analysis. Significance is marked by *.
BOR, best overall response; OS, overall survival; PFS, progression- free survival; SNPs, single- nucleotide polymorphisms; WHO PS, WHO 
performance status.
Besides germline polymorphisms in the GZMB gene, 
polymorphisms in other genes have been investigated 
as well for their association with clinical outcome. Inter-
estingly, these germline variations were not consistently 
found to correlate with PFS, OS, or BOR. Interpretations 
of these findings are challenging, and do not neces-
sarily implicate an absence of effects of non- GZMB SNPs. 
Although SNPs were rationally selected by their correla-
tions with autoimmunity (online supplementary table 2), 
we cannot exclude that SNPs in the investigated genes 
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Figure 2 Association between serum granzyme B and T cell populations with phenotypes that correspond to functional 
responses. Associations are shown between (A) serum granzyme B levels or (B) GZMB genotype and T cell populations in 
blood. CD8+ T cells is considered as a subset of T lymphocytes with cytotoxic functions. CCR7−CD45RA+ cytotoxic T cells 
correspond with terminal differentiation, and PD1+TIM3+ cytotoxic T cells correspond with exhaustion, both signs of T cell 
activation or cytotoxicity. HET, heterozygous variant; HVAR, homozygous variant; WT, wild type.
Figure 3 Mechanism of action. Schematic overview of the proposed mechanism of action of the GZMB SNP. Presence of the 
GZMB c.128T>C SNP indicates the expression of variant granzyme B isotypes (indicated as pink granzyme B molecules) that 
might lead to impaired cytotoxic effector functions of T cells, resulting in impaired apoptosis of tumor cells and partial resistance 
to anti- PD-1 blockade. The molecular mechanism of the PD-1 antibody nivolumab is shown in the white box. This figure was 
created by DPH in BioRender.com. PD-1, programmed cell death 1 receptor; SNP, single- nucleotide polymorphism.
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contribute to therapy resistance, as well as epigenetic 
or post- transcriptional regulation of gene expression or 
function. For example, PD-1 ICIs are suggested to only 
minimally target responses mediated by T cell recep-
tors (involving ZAP70) and their primary method of 
action is most likely explained by relieving SHP-2 inhi-
bition of the CD28 costimulatory pathway.8 Genomic 
alterations in tumors may involve loss of tumor antigens 
that are recognized by T cells, loss of antigen- presenting 
machinery components, tumor- induced inactivation of 
T cell signaling and insensitivity to effector functions of 
lymphocytes, death receptors or interferons.34
The nonsynonymous substitution of GZMB c.128T>C 
(rs8192917) was found to be in strong linkage disequilib-
rium with other common (MAF >15%) exonic variants, 
representing a haplotype block (data publicly available 
from The Single Nucleotide Polymorphism Database 
(https://www. ncbi. nlm. nih. gov/ snp/; online supple-
mentary figure 3). This indicates that two predominant 
isoforms of granzyme B are expressed in the European 
population, defining two predominant isoforms, and is 
consistent with previous reports that genetic variation 
of GZMB leads to change of three amino acids of the 
mature protein (Q48P88Y245 to R48A88H245).15 35 Interest-
ingly, the two isoforms have a similar expression, stability 
and proteolytic activity, however, the variant granzyme B 
isotype was observed to be incapable of inducing apop-
tosis in tumor cell lines in contrast to the functional 
effects of the more common isotype.36
Interaction analysis between granzyme B, expression 
of PD- L1 in tumor and TMB showed that these markers 
were not intercorrelated, which suggests their value as 
independent biomarkers for clinical outcome after PD-1 
ICIs. Although our findings in regard to serum granzyme 
B and GZMB germline variation are confirmed in a large 
patient cohort and by internal validation, further investi-
gations need to be performed to determine the clinical 
value as a predictive or prognostic biomarker of response 
to PD-1 blockade. These investigations include compar-
ative analysis with these currently used biomarkers in an 
extended patient cohort, and evaluation of the diagnostic 
accuracy and mapping of the sensitivity of serum gran-
zyme B in a prospective clinical trial. The results may not 
be directly applicable to other ethnic groups, as the study 
was performed in a European population.
An important aspect of our results is that germline 
genetics related to cytotoxic effector functions of lympho-
cytes contribute to mechanisms of resistance to ICI 
therapy. Previously, it has been shown that germline varia-
tions in regard to the antigen presentation machinery are 
related to response to ICIs, that is HLA-1 heterozygosity.37 
Considering the urgent need to understand how genetic 
variation affects response to ICIs, as reviewed by Havel 
et al,5 further work is warranted to identify novel genetic 
loci. We believe that apart from genes that are involved 
in antigen presentation, other immune- modulating 
genes may also contribute to response and resistance 
mechanisms of ICIs, of which granzyme B is an example. 
Determination of germline variations of patients with 
cancer contributing to response to ICIs may well be 
performed by future genome- wide association studies.
ConCLusions
While the immune- oncology field rapidly advances, our 
understanding of ICI resistance mechanisms is limited 
and effective patient selection is lacking. Our data demon-
strate that granzyme B is an important player in the anti-
tumor immunity, as a consequence of the finding that low 
serum levels of granzyme B and germline variation of the 
GZMB gene contributes to resistance to PD-1 blockade in 
advanced NSCLC. As recent clinical trial results under-
line effective biomarker- based patient selection, future 
trials that incorporate granzyme B into diagnostics are 
considered as a promising step in this direction.
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